Literature DB >> 16620788

Structure-activity relationship for nucleoside analogs as inhibitors or substrates of adenosine kinase from Mycobacterium tuberculosis. I. Modifications to the adenine moiety.

Mary C Long1, William B Parker.   

Abstract

Adenosine kinase (Ado kinase, EC 2.7.1.20) is a purine salvage enzyme that phosphorylates adenosine (Ado) to AMP. Ado kinase from Mycobacterium tuberculosis also catalyzes an essential step in the conversion of 2-methyl-Ado to a compound with selective antimycobacterial activity. In order to aid in the design of more potent and selective Ado analogs, eighty nucleoside analogs with modifications to the adenine (Ade) moiety of Ado were evaluated as both substrates and inhibitors of Ado kinase from M. tuberculosis, and a subset was further tested with human Ado kinase for the sake of comparison. The best substrates were 2-aza-Ado, 8-aza-9-deaza-Ado, and 2-fluoro-Ado and the most potent inhibitors were N1-benzyl-Ado (Ki=0.19 microM), 2-fluoro-Ado (Ki=0.5 microM), 6-cyclopentyloxy-purine riboside (Ki=0.15 microM), and 7-iodo-7-deaza-Ado (Ki=0.21 microM). These studies revealed the presence of a hydrophobic pocket near the N6- and N1-positions that can accommodate substitutions at least as large as a benzyl group. The ability to fit into this pocket increased the likelihood that a compound would be an inhibitor and not a substrate. The 2-position was able to accommodate exocyclic substitutions as large as a methoxy group, although substrate activity was low. Similarly, the 7-position could bind an exocyclic group as large as a carboxamido moiety. However, all of the compounds tested with modifications at the 7-position were much better inhibitors than substrates. MIC studies performed with selected compounds have yielded several Ado analogs with promising antitubercular activity. Future studies will utilize this information for the design of new analogs that may be selective antitubercular agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16620788     DOI: 10.1016/j.bcp.2006.03.006

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  14 in total

1.  Identification of the Formycin A Biosynthetic Gene Cluster from Streptomyces kaniharaensis Illustrates the Interplay between Biological Pyrazolopyrimidine Formation and de Novo Purine Biosynthesis.

Authors:  Shao-An Wang; Yeonjin Ko; Jia Zeng; Yujie Geng; Daan Ren; Yasushi Ogasawara; Seema Irani; Yan Zhang; Hung-Wen Liu
Journal:  J Am Chem Soc       Date:  2019-04-08       Impact factor: 15.419

2.  Efficient radiosynthesis of 2-[(18)f]fluoroadenosine: a new route to 2-[(18)f]fluoropurine nucleosides.

Authors:  Patrice Marchand; Christophe Lorilleux; Gwénaëlle Gilbert; Fabienne Gourand; Franck Sobrio; Damien Peyronnet; Martine Dhilly; Louisa Barré
Journal:  ACS Med Chem Lett       Date:  2010-05-28       Impact factor: 4.345

3.  Identification of the C-Glycoside Synthases during Biosynthesis of the Pyrazole-C-Nucleosides Formycin and Pyrazofurin.

Authors:  Daan Ren; Shao-An Wang; Yeonjin Ko; Yujie Geng; Yasushi Ogasawara; Hung-Wen Liu
Journal:  Angew Chem Int Ed Engl       Date:  2019-10-07       Impact factor: 15.336

4.  Computer-assisted combinatorial design of bicyclic thymidine analogs as inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase.

Authors:  Vladimir Frecer; Pierfausto Seneci; Stanislav Miertus
Journal:  J Comput Aided Mol Des       Date:  2010-11-17       Impact factor: 3.686

5.  Identification and Characterization of Enzymes Catalyzing Pyrazolopyrimidine Formation in the Biosynthesis of Formycin A.

Authors:  Yeonjin Ko; Shao-An Wang; Yasushi Ogasawara; Mark W Ruszczycky; Hung-Wen Liu
Journal:  Org Lett       Date:  2017-02-24       Impact factor: 6.005

Review 6.  Adenosine kinase: exploitation for therapeutic gain.

Authors:  Detlev Boison
Journal:  Pharmacol Rev       Date:  2013-04-16       Impact factor: 25.468

7.  Structure-activity relationship for adenosine kinase from Mycobacterium tuberculosis II. Modifications to the ribofuranosyl moiety.

Authors:  Mary C Long; Sue C Shaddix; Omar Moukha-Chafiq; Joseph A Maddry; Lisa Nagy; William B Parker
Journal:  Biochem Pharmacol       Date:  2008-02-02       Impact factor: 5.858

8.  High-throughput nano-biofilm microarray for antifungal drug discovery.

Authors:  Anand Srinivasan; Kai P Leung; Jose L Lopez-Ribot; Anand K Ramasubramanian
Journal:  MBio       Date:  2013-06-25       Impact factor: 7.867

9.  Interaction of Rio1 kinase with toyocamycin reveals a conformational switch that controls oligomeric state and catalytic activity.

Authors:  Irene N Kiburu; Nicole LaRonde-LeBlanc
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

10.  Chemotherapeutic interventions against tuberculosis.

Authors:  Neeraj Shakya; Gaurav Garg; Babita Agrawal; Rakesh Kumar
Journal:  Pharmaceuticals (Basel)       Date:  2012-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.